Abstract
Background: Relapsing, refractory patients with idiopathic hypereosinophilic syndrome (I-HES) and chronic eosinophilic leukemia-not otherwise specified (CEL-NOS) do not have many effective, durable therapeutic options. Alemtuzumab, an anti-CD52 antibody, has been reported to be an effective therapy due to inherent expression of CD52 on eosinophils. Methods: A retrospective chart review of 12 patients treated with alemtuzumab at our center until 2012. Results: Ten (83%) of 12 patients achieved complete hematologic response (CHR) after a median of 1 week for a median duration of 66 weeks, with the elimination of disease-related symptoms; 2 patients achieved partial hematologic remission hematologic remission (PHR). Patients with CHR who received alemtuzumab maintenance (n = 5) had a significantly longer time to progression than those patients who were only observed (n = 5) (P =.01). Eleven patients relapsed (only one while on maintenance), and 6 were rechallenged with alemtuzumab. Five (83%) achieved second CHR after a median of 3.5 weeks, for a median duration of 123 weeks. Again, those given maintenance (n = 3) had a longer time to progression than those who were only observed (P =.04). Adverse effects were mostly related to infusion reactions and lymphopenia-related viral infections (despite antibiotic prophylaxis). One patient developed Epstein-Barr virus-related lymphoma. Conclusions: Alemtuzumab is an effective treatment for patients with relapsed, refractory idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia-not otherwise specified, in terms of both CHR achievement (even after repeated rechallenges) and duration (particularly if provided as a maintenance therapy). Common adverse effects are related to infusion reactions and immunosuppression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 287-291 |
| Number of pages | 5 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 13 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 1 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- Alemtuzumab
- Chronic eosinophilic leukemia
- Idiopathic hypereosinophilic syndrome
- Therapy
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Long-term follow-up of patients with hypereosinophilic syndrome treated with alemtuzumab, an anti-CD52 antibody. / Strati, Paolo; Cortes, Jorge; Faderl, Stefan; Kantarjian, Hagop; Verstovsek, Srdan.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 3, 01.06.2013, p. 287-291.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term follow-up of patients with hypereosinophilic syndrome treated with alemtuzumab, an anti-CD52 antibody
AU - Strati, Paolo
AU - Cortes, Jorge
AU - Faderl, Stefan
AU - Kantarjian, Hagop
AU - Verstovsek, Srdan
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Background: Relapsing, refractory patients with idiopathic hypereosinophilic syndrome (I-HES) and chronic eosinophilic leukemia-not otherwise specified (CEL-NOS) do not have many effective, durable therapeutic options. Alemtuzumab, an anti-CD52 antibody, has been reported to be an effective therapy due to inherent expression of CD52 on eosinophils. Methods: A retrospective chart review of 12 patients treated with alemtuzumab at our center until 2012. Results: Ten (83%) of 12 patients achieved complete hematologic response (CHR) after a median of 1 week for a median duration of 66 weeks, with the elimination of disease-related symptoms; 2 patients achieved partial hematologic remission hematologic remission (PHR). Patients with CHR who received alemtuzumab maintenance (n = 5) had a significantly longer time to progression than those patients who were only observed (n = 5) (P =.01). Eleven patients relapsed (only one while on maintenance), and 6 were rechallenged with alemtuzumab. Five (83%) achieved second CHR after a median of 3.5 weeks, for a median duration of 123 weeks. Again, those given maintenance (n = 3) had a longer time to progression than those who were only observed (P =.04). Adverse effects were mostly related to infusion reactions and lymphopenia-related viral infections (despite antibiotic prophylaxis). One patient developed Epstein-Barr virus-related lymphoma. Conclusions: Alemtuzumab is an effective treatment for patients with relapsed, refractory idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia-not otherwise specified, in terms of both CHR achievement (even after repeated rechallenges) and duration (particularly if provided as a maintenance therapy). Common adverse effects are related to infusion reactions and immunosuppression.
AB - Background: Relapsing, refractory patients with idiopathic hypereosinophilic syndrome (I-HES) and chronic eosinophilic leukemia-not otherwise specified (CEL-NOS) do not have many effective, durable therapeutic options. Alemtuzumab, an anti-CD52 antibody, has been reported to be an effective therapy due to inherent expression of CD52 on eosinophils. Methods: A retrospective chart review of 12 patients treated with alemtuzumab at our center until 2012. Results: Ten (83%) of 12 patients achieved complete hematologic response (CHR) after a median of 1 week for a median duration of 66 weeks, with the elimination of disease-related symptoms; 2 patients achieved partial hematologic remission hematologic remission (PHR). Patients with CHR who received alemtuzumab maintenance (n = 5) had a significantly longer time to progression than those patients who were only observed (n = 5) (P =.01). Eleven patients relapsed (only one while on maintenance), and 6 were rechallenged with alemtuzumab. Five (83%) achieved second CHR after a median of 3.5 weeks, for a median duration of 123 weeks. Again, those given maintenance (n = 3) had a longer time to progression than those who were only observed (P =.04). Adverse effects were mostly related to infusion reactions and lymphopenia-related viral infections (despite antibiotic prophylaxis). One patient developed Epstein-Barr virus-related lymphoma. Conclusions: Alemtuzumab is an effective treatment for patients with relapsed, refractory idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia-not otherwise specified, in terms of both CHR achievement (even after repeated rechallenges) and duration (particularly if provided as a maintenance therapy). Common adverse effects are related to infusion reactions and immunosuppression.
KW - Alemtuzumab
KW - Chronic eosinophilic leukemia
KW - Idiopathic hypereosinophilic syndrome
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=84877783714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877783714&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2012.09.018
DO - 10.1016/j.clml.2012.09.018
M3 - Article
C2 - 23123105
AN - SCOPUS:84877783714
VL - 13
SP - 287
EP - 291
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2650
IS - 3
ER -